Replies to post #508519 on Anavex Life Sciences Corp (AVXL)

[ExtremelyBullishZig]

Only problem...the trials were flawed, under powered, and poorly designed, so your numbers are all null and void. 
A properly designed trial will clear this up once and for all and my measly few shares that I have left will get me back to where I was before I started investing in AVXL...upon approval.

[Hosai]

Safe to say Nf-L endpoint not a strong point for Donanemab:

From Donanemab phase 2 - "No significant differences in plasma levels of amyloid-ß 42/40 and neurofilament light chain were observed between treatment arms at the end of treatment."
https://jamanetwork.com/journals/jamaneurology/fullarticle/2797022

From Donanemab phase 3 in FDA briefing doc - " No treatment difference was observed for plasma NfL at Week 76, but a larger
increase was observed in the donanemab arm compared to placebo at Weeks 12 and 24."
https://www.fda.gov/media/179166/download?utm_source